

John Berdahl, MD Updated 6/2/2025
Financial Disclosure List

Company	C	O	O*	P		Date	Other
AbbVie	C					11/4/2021	Glaucoma
Aerpio	C					2/27/2020	
ALJ Health	C						
Alcon	C					1/1/2011	Glaucoma
Aldeyra	C						
Aquea Health	C	O					
Aurion Biotech	C	O				3/1/2017	
Avelino	C						
Balance Ophthalmics	C	O	*	P		4/14/2023	Glaucoma
Bausch And Lomb	C					1/1/2011	Glaucoma
Belkin	C						
CorneaGen	C	O				3/1/2017	
Dakota Lions Eye Bank	C					1/1/2010	
Elios Vision INC	C	O				4/1/2022	Glaucoma
Expert Opinion	C	O	*			6/1/2018	
Glaukos	C	O	*	P		1/1/2012	Glaucoma
Gore	C						
Greenman	C	O	*			3/12/2024	Glaucoma
Horizon Surgical	C						
Iacta Pharmaceuticals	C	O				10/3/2020	
Imprimis	C			P		1/1/2015	
iRenix	C					9/21/2019	

IVERIC bio, Inc	C					4/24/2023	
JNJ	C					1/1/2012	
Kala	C						
LayerBio	C	O					
MELT Pharmaceuticals	C	O	*	P			
MicroOptx	C						Glaucoma
New World Medical	C					1/1/2016	
Ocular Surgical Data	C	O	*			1/1/2013	
Ocular Therapeutix	C					1/1/2016	
Omega Ophthalmic	C	O				1/1/2014	Glaucoma
Orasis	C	O				8/20/2018	
Oyster Point	C	O					
RxSight	C						Glaucoma
Santen	C					8/25/2022	Glaucoma
Sight Sciences	C						
Tarsus	C						
TavoBio	C	O				4/13/2024	
Tear Clear	C	O					
Tissue Gen	C						
True North CRO		O				7/10/2023	Glaucoma
Vance Thompson Vision		O				8/1/2009	
Verana Health	C	O					
Versea Biologics	C					7/7/2022	
Vertex Ventures	C					10/30/2020	
ViaLase	C	O				4/1/2019	

C = Consultant/Advisor Consultant Fee, paid advisory boards or fees for attending a meeting for the past 1 year

E = Employee Employed by a commercial entity

O Equity ownership/stock options of publicacly or pritately traded firms (excluding mutual funds) with manufacturers of commercial ophthalmic products or commercial ophthalmic services.

O* - Equity ownership not in the form of options.

P Patents /Royalty - Patents and/or royalties that might be reviewed as creating a potential conflict of interest.